Key result
Post-MI secondary prevention prescribing is high, reaching ~97% for aspirin mostly initiated at discharge.
Why the study?
Clinical trials have shown secondary prevention after myocardial infarction is effective, but implementation in routine practice may be inadequate.
What are the implementation rates of evidence-based secondary prevention measures in routine clinical practice for patients surviving an acute myocardial infarction?
Population
608 patients aged less than 80 years surviving more than 28 days after acute myocardial infarction in Oxfordshire, UK
Comparison
Secondary prevention measures including aspirin, β-blockers, ACE inhibitors, and lifestyle advice
Design
Cohort study
Authors
Loading...
Incomplete adoption of lifestyle advice and monitoring persists post-MI; leaves open whether coordinated primary-secondary care improves implementation.
Cohort (n=608)
What are the implementation rates of evidence-based secondary prevention measures in routine clinical practice for patients surviving an acute myocardial infarction?
Hospital-initiated prescribing achieves high rates of adherence to evidence-based drug therapy for secondary prevention after myocardial infarction, though lifestyle advice provision remains suboptimal.
Dovey et al. (1998) conducted a cohort in Myocardial Infarction (n=608). Secondary prevention guidelines implementation was evaluated on Prescription rates of secondary prevention medications and lifestyle advice. In a cohort of 608 post-myocardial infarction patients, secondary prevention prescribing was high (97% for aspirin, 66% for beta-blockers, 85% for ACE inhibitors), mostly initiated at discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: